Ceftazidime in Overwhelming Pediatric Infections

劉 清泉(Ching-Chuan Liu), 洪 俊源(Jin-Yang Hong), 李 慶雲(Chin-Yun Lee), 林 凱信(Kai-Hsin Lin), 李 明鎮(Ming-Jenn Lee), 許 靜瑛(Ching-Ying Hsu), 林 奏延(Tzou-Yien Lin), 黃 立民(Li-Min Huang), 林 國信(Kuo-Sin Lin)

Research output: Contribution to journalArticle

Abstract

An experience with ceftazidime in the treatment of newborns, young infants, and immunocompromised or neutropenic children is presented. A total of 24 seriously ill pediatric Patients with septicemia, cellulitis, pneumonia, peritonitis or meningitis were selected for the study. Patients were treated with dosages ranging between 90 and 150mg/kg per day for 7 to 50 days.
The patients were divided into three groups: Group 1 comprised nine normal hosts, including four newborns and five infants; Group 2 included ten compromised or neutropenic hosts after immunosuppressive treatments; seven of them were acute leukemia, one malignant teratoma, one Leiner's disease, and one nephrotic syndrome; Group 3 were five febrile neutropenic bone marrow transplant patients.
Bacteriologic etiologies were Pseudomonas aeruginosa in 12 episodes, P. aeruginosa plus Staphylococcus aureus in 1, E. coli in 2, Klebsiella pneumoniae in 2, Enterobacter aerogenes in 1, and one episode of polymicrobial infection with P. aeruginosa plus E. coli and Bacteroides fragilis. No microorganism isolation was found in five of the patients. The clinical efficacy in normal hosts with ceftazidime monotherapy was 89 percent, with only one failure due to polymicrobial infection. Among the 15 compromised or neutropenic hosts, 12 (80 percent) were cured or improved with bacterial eradication, 2 improved initially but died of superinfection subsequently and 1 died of pneumonia with empyema due to a resistant strain of P. aeruginosa.
The overall cure or improvement rate was 83.4 percent (two superinfections ercluded). It is important to emphasize that 11 (91.7%) of 12 cases with P. aeruginosa infection were cured (9 cases) or improved (2 cases) after ceftazidime treatment. No significant toxicities were noted.
These data suggest that ceftazidime is safe and effective in the treatment of aerobic gram-negative, especially P. aeruginosa, infections in newborns, young infants and immunocompromised or neutropenic children.
Original languageEnglish
Pages (from-to)420-429
Number of pages10
JournalActa Paediatrica Sinica
Volume28
Issue number6
Publication statusPublished - 1987
Externally publishedYes

Fingerprint

Ceftazidime
Pseudomonas aeruginosa
Pediatrics
Infection
Pseudomonas Infections
Superinfection
Newborn Infant
Coinfection
Pneumonia
Escherichia coli
Enterobacter aerogenes
Bacteroides fragilis
Empyema
Cellulitis
Teratoma
Klebsiella pneumoniae
Nephrotic Syndrome
Therapeutics
Immunosuppressive Agents
Peritonitis

Keywords

  • Ceftazidime
  • neonatal infections
  • immunocompromised host
  • febrile neutropenic patient
  • Pseudomonas aeruginosa

Cite this

劉清泉(Ching-Chuan L, 洪俊源(Jin-Yang H, 李慶雲(Chin-Yun L, 林凱信(Kai-Hsin L, 李明鎮(Ming-Jenn L, 許靜瑛(Ching-Ying H, ... 林國信(Kuo-Sin L (1987). Ceftazidime in Overwhelming Pediatric Infections. Acta Paediatrica Sinica, 28(6), 420-429.

Ceftazidime in Overwhelming Pediatric Infections. / 劉清泉(Ching-Chuan Liu); 洪俊源(Jin-Yang Hong); 李慶雲(Chin-Yun Lee); 林凱信(Kai-Hsin Lin); 李明鎮(Ming-Jenn Lee); 許靜瑛(Ching-Ying Hsu); 林奏延(Tzou-Yien Lin); 黃立民(Li-Min Huang); 林國信(Kuo-Sin Lin).

In: Acta Paediatrica Sinica, Vol. 28, No. 6, 1987, p. 420-429.

Research output: Contribution to journalArticle

劉清泉(Ching-ChuanL, 洪俊源(Jin-YangH, 李慶雲(Chin-YunL, 林凱信(Kai-HsinL, 李明鎮(Ming-JennL, 許靜瑛(Ching-YingH, 林奏延(Tzou-YienL, 黃立民(Li-MinH & 林國信(Kuo-SinL 1987, 'Ceftazidime in Overwhelming Pediatric Infections', Acta Paediatrica Sinica, vol. 28, no. 6, pp. 420-429.
劉清泉(Ching-ChuanL, 洪俊源(Jin-YangH, 李慶雲(Chin-YunL, 林凱信(Kai-HsinL, 李明鎮(Ming-JennL, 許靜瑛(Ching-YingH et al. Ceftazidime in Overwhelming Pediatric Infections. Acta Paediatrica Sinica. 1987;28(6):420-429.
劉清泉(Ching-Chuan Liu) ; 洪俊源(Jin-Yang Hong) ; 李慶雲(Chin-Yun Lee) ; 林凱信(Kai-Hsin Lin) ; 李明鎮(Ming-Jenn Lee) ; 許靜瑛(Ching-Ying Hsu) ; 林奏延(Tzou-Yien Lin) ; 黃立民(Li-Min Huang) ; 林國信(Kuo-Sin Lin). / Ceftazidime in Overwhelming Pediatric Infections. In: Acta Paediatrica Sinica. 1987 ; Vol. 28, No. 6. pp. 420-429.
@article{7cac2084512e4aa4a3ea5a81072a90cc,
title = "Ceftazidime in Overwhelming Pediatric Infections",
abstract = "An experience with ceftazidime in the treatment of newborns, young infants, and immunocompromised or neutropenic children is presented. A total of 24 seriously ill pediatric Patients with septicemia, cellulitis, pneumonia, peritonitis or meningitis were selected for the study. Patients were treated with dosages ranging between 90 and 150mg/kg per day for 7 to 50 days.The patients were divided into three groups: Group 1 comprised nine normal hosts, including four newborns and five infants; Group 2 included ten compromised or neutropenic hosts after immunosuppressive treatments; seven of them were acute leukemia, one malignant teratoma, one Leiner's disease, and one nephrotic syndrome; Group 3 were five febrile neutropenic bone marrow transplant patients.Bacteriologic etiologies were Pseudomonas aeruginosa in 12 episodes, P. aeruginosa plus Staphylococcus aureus in 1, E. coli in 2, Klebsiella pneumoniae in 2, Enterobacter aerogenes in 1, and one episode of polymicrobial infection with P. aeruginosa plus E. coli and Bacteroides fragilis. No microorganism isolation was found in five of the patients. The clinical efficacy in normal hosts with ceftazidime monotherapy was 89 percent, with only one failure due to polymicrobial infection. Among the 15 compromised or neutropenic hosts, 12 (80 percent) were cured or improved with bacterial eradication, 2 improved initially but died of superinfection subsequently and 1 died of pneumonia with empyema due to a resistant strain of P. aeruginosa.The overall cure or improvement rate was 83.4 percent (two superinfections ercluded). It is important to emphasize that 11 (91.7{\%}) of 12 cases with P. aeruginosa infection were cured (9 cases) or improved (2 cases) after ceftazidime treatment. No significant toxicities were noted.These data suggest that ceftazidime is safe and effective in the treatment of aerobic gram-negative, especially P. aeruginosa, infections in newborns, young infants and immunocompromised or neutropenic children.",
keywords = "Ceftazidime, neonatal infections, immunocompromised host, febrile neutropenic patient, Pseudomonas aeruginosa",
author = "劉, {清泉(Ching-Chuan Liu)} and 洪, {俊源(Jin-Yang Hong)} and 李, {慶雲(Chin-Yun Lee)} and 林, {凱信(Kai-Hsin Lin)} and 李, {明鎮(Ming-Jenn Lee)} and 許, {靜瑛(Ching-Ying Hsu)} and 林, {奏延(Tzou-Yien Lin)} and 黃, {立民(Li-Min Huang)} and 林, {國信(Kuo-Sin Lin)}",
year = "1987",
language = "English",
volume = "28",
pages = "420--429",
journal = "Pediatrics and Neonatology",
issn = "1875-9572",
publisher = "臺灣兒科醫學會",
number = "6",

}

TY - JOUR

T1 - Ceftazidime in Overwhelming Pediatric Infections

AU - 劉, 清泉(Ching-Chuan Liu)

AU - 洪, 俊源(Jin-Yang Hong)

AU - 李, 慶雲(Chin-Yun Lee)

AU - 林, 凱信(Kai-Hsin Lin)

AU - 李, 明鎮(Ming-Jenn Lee)

AU - 許, 靜瑛(Ching-Ying Hsu)

AU - 林, 奏延(Tzou-Yien Lin)

AU - 黃, 立民(Li-Min Huang)

AU - 林, 國信(Kuo-Sin Lin)

PY - 1987

Y1 - 1987

N2 - An experience with ceftazidime in the treatment of newborns, young infants, and immunocompromised or neutropenic children is presented. A total of 24 seriously ill pediatric Patients with septicemia, cellulitis, pneumonia, peritonitis or meningitis were selected for the study. Patients were treated with dosages ranging between 90 and 150mg/kg per day for 7 to 50 days.The patients were divided into three groups: Group 1 comprised nine normal hosts, including four newborns and five infants; Group 2 included ten compromised or neutropenic hosts after immunosuppressive treatments; seven of them were acute leukemia, one malignant teratoma, one Leiner's disease, and one nephrotic syndrome; Group 3 were five febrile neutropenic bone marrow transplant patients.Bacteriologic etiologies were Pseudomonas aeruginosa in 12 episodes, P. aeruginosa plus Staphylococcus aureus in 1, E. coli in 2, Klebsiella pneumoniae in 2, Enterobacter aerogenes in 1, and one episode of polymicrobial infection with P. aeruginosa plus E. coli and Bacteroides fragilis. No microorganism isolation was found in five of the patients. The clinical efficacy in normal hosts with ceftazidime monotherapy was 89 percent, with only one failure due to polymicrobial infection. Among the 15 compromised or neutropenic hosts, 12 (80 percent) were cured or improved with bacterial eradication, 2 improved initially but died of superinfection subsequently and 1 died of pneumonia with empyema due to a resistant strain of P. aeruginosa.The overall cure or improvement rate was 83.4 percent (two superinfections ercluded). It is important to emphasize that 11 (91.7%) of 12 cases with P. aeruginosa infection were cured (9 cases) or improved (2 cases) after ceftazidime treatment. No significant toxicities were noted.These data suggest that ceftazidime is safe and effective in the treatment of aerobic gram-negative, especially P. aeruginosa, infections in newborns, young infants and immunocompromised or neutropenic children.

AB - An experience with ceftazidime in the treatment of newborns, young infants, and immunocompromised or neutropenic children is presented. A total of 24 seriously ill pediatric Patients with septicemia, cellulitis, pneumonia, peritonitis or meningitis were selected for the study. Patients were treated with dosages ranging between 90 and 150mg/kg per day for 7 to 50 days.The patients were divided into three groups: Group 1 comprised nine normal hosts, including four newborns and five infants; Group 2 included ten compromised or neutropenic hosts after immunosuppressive treatments; seven of them were acute leukemia, one malignant teratoma, one Leiner's disease, and one nephrotic syndrome; Group 3 were five febrile neutropenic bone marrow transplant patients.Bacteriologic etiologies were Pseudomonas aeruginosa in 12 episodes, P. aeruginosa plus Staphylococcus aureus in 1, E. coli in 2, Klebsiella pneumoniae in 2, Enterobacter aerogenes in 1, and one episode of polymicrobial infection with P. aeruginosa plus E. coli and Bacteroides fragilis. No microorganism isolation was found in five of the patients. The clinical efficacy in normal hosts with ceftazidime monotherapy was 89 percent, with only one failure due to polymicrobial infection. Among the 15 compromised or neutropenic hosts, 12 (80 percent) were cured or improved with bacterial eradication, 2 improved initially but died of superinfection subsequently and 1 died of pneumonia with empyema due to a resistant strain of P. aeruginosa.The overall cure or improvement rate was 83.4 percent (two superinfections ercluded). It is important to emphasize that 11 (91.7%) of 12 cases with P. aeruginosa infection were cured (9 cases) or improved (2 cases) after ceftazidime treatment. No significant toxicities were noted.These data suggest that ceftazidime is safe and effective in the treatment of aerobic gram-negative, especially P. aeruginosa, infections in newborns, young infants and immunocompromised or neutropenic children.

KW - Ceftazidime

KW - neonatal infections

KW - immunocompromised host

KW - febrile neutropenic patient

KW - Pseudomonas aeruginosa

M3 - Article

VL - 28

SP - 420

EP - 429

JO - Pediatrics and Neonatology

JF - Pediatrics and Neonatology

SN - 1875-9572

IS - 6

ER -